Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA)-Reference-Cited by-同舟云学术

Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA)

Published:2019-03-14 Issue:2 Volume:33 Page:193-205
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Hermosilla Jesús,Sánchez-Martín Ricardo,Pérez-Robles Raquel,Salmerón-García Antonio,Casares Salvador,Cabeza Jose,Cuadros-Rodríguez Luis,Navas Natalia^ORCID

Funder

Instituto de Salud Carlos III

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-019-00342-9.pdf

Reference29 articles.

1. Committee for Medicinal Products for Human Use. Remsima assessment report EMA/CHMP/589317/2013. 2013. https://www.ema.europa.eu/documents/assessment-report/remsima-epar-public-assessment-report_en.pdf . Accessed 20 Nov 2018.

2. Committee for Medicinal Products for Human Use. Inflectra assessment report EMA/CHMP/589422/2013. 2013. https://www.ema.europa.eu/documents/assessment-report/inflectra-epar-public-assessment-report_en.pdf . Accessed 20 Nov 2018.

3. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121–36.

4. Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol. 2000;12:582–7.

5. Blair HA, Deeks ED. Infliximab biosimilar (CT-P13; infliximab-dyyb): a review in autoimmune inflammatory diseases. BioDrugs. 2016;30:469–80.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Regulatory Perspective on Biosimilar Medicines;Pharmaceutics;2024-02-25

2. Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: Impact on antigen–antibody binding;European Journal of Pharmaceutics and Biopharmaceutics;2024-01

3. Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers;Journal of Pharmaceutical and Biomedical Analysis;2022-11

4. Combined use of UV and MS data for ICH Stability-Indication Method: Quantification and isoforms identification of intact nivolumab;Microchemical Journal;2022-11

5. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress;Pharmaceutics;2022-03-23